tradmap

IBO Earnings IMPACT BIOMEDICAL INC.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$28 -$14 $0 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $25000 $50000 2022 2023 2024 2025
Revenue
Net income (annual)
-$25M -$12M $0 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$26 -$7 $12 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $9000 $18000 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$27M -$11M $5M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–20 of 20
Q2 20262026-06-30-0.122026-08-0710-Q
Q1 20262026-03-31-0.242026-05-1210-Q
Q4 2025 (derived)2025-12-3112.362026-03-1110-K
FY 20252025-12-31-4.562026-03-1110-K
Q3 20252025-09-30-1.442025-11-0710-Q
Q2 20252025-06-30-14.162025-08-1410-Q
Q1 20252025-03-31-1.322025-05-1410-Q
Q4 2024 (derived)2024-12-31-26.042025-03-2810-K
FY 20242024-12-31-27.602025-03-2810-K
Q3 20242024-09-300.722024-11-1210-Q
Q2 20242024-06-30-1.082024-08-1310-Q
Q1 20242024-03-31-1.202024-05-1010-Q
Q4 2023 (derived)2023-12-31-0.242024-02-2010-K
FY 20232023-12-31-0.842024-02-2010-K
Q3 20232023-09-30-0.242023-11-1310-Q
Q2 20232023-06-30-0.242023-10-0510-Q
Q1 20232023-03-31-0.12——
FY 20222022-12-31-1.20——
Q3 20222022-09-30-0.36——
Q2 20222022-06-300.00——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.